Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Secotex®
- Registration Number
- NCT02244346
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 811
Inclusion Criteria
- Patients of any age with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH)
- Patients with symptoms, that according to physician require medical treatment to improve quality of life
- Patients could be naive to treatment or could be on treatment with other drugs but have not responded adequately to treatment
Exclusion Criteria
- Patients with known hypersensitivity to Tamsulosin, or any other component of the product
- Patients with a history of orthostatic hypotension or severe liver failure
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Benign prostatic hyperplasia patients Secotex® -
- Primary Outcome Measures
Name Time Method Number of patients with adverse events up to 6 months
- Secondary Outcome Measures
Name Time Method